OncoMatch/Clinical Trials/NCT07057427
Efficacy of Nab-PHP Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer
Is NCT07057427 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Nab paclitaxel and Docetaxel and Carboplatin for breast cancer.
Treatment: Nab paclitaxel · Docetaxel and Carboplatin · Trastuzumab + Pertuzumab — The aim of this study is to evaluate the efficacy of nab-paclitaxel (on days 1 and 8 of a 21-day cycle) compared to the standard regimen of docetaxel plus carboplatin, both combined with trastuzumab and pertuzumab, as neoadjuvant therapies for HER2-positive breast cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Biomarker criteria
Required: HER2 (ERBB2) overexpression (ihc 3+ or fish positive)
Disease stage
Required: Stage T4C, T4D, T1C WITH AXILLARY LYMPH NODE POSITIVITY (AJCC TNM)
Excluded: Stage IV
Clinical Tumor Stage: T2-T4d, or T1c with axillary lymph node positivity. Stage IV (metastatic) breast cancer [excluded].
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic therapy
Prior systemic therapy or radiotherapy for the current breast cancer diagnosis, including chemotherapy, endocrine therapy, or targeted therapy
Cannot have received: radiation therapy
Prior systemic therapy or radiotherapy for the current breast cancer diagnosis, including chemotherapy, endocrine therapy, or targeted therapy
Lab requirements
Blood counts
ANC ≥ 2.0 × 10⁹/L; Hemoglobin ≥ 100 g/L; Platelet count ≥ 100 × 10⁹/L
Kidney function
Serum creatinine < 1.5 × ULN
Liver function
Total bilirubin < 1.5 × ULN; AST/ALT < 1.5 × ULN
Cardiac function
LVEF ≥ 55% assessed by echocardiography
Adequate organ and bone marrow function within 1 month prior to chemotherapy initiation (no contraindications to chemotherapy): 1. Absolute neutrophil count (ANC) ≥ 2.0 × 10⁹/L 2. Hemoglobin ≥ 100 g/L 3. Platelet count ≥ 100 × 10⁹/L 4. Total bilirubin < 1.5 × ULN 5. Serum creatinine < 1.5 × ULN 6. AST/ALT < 1.5 × ULN. Cardiac function: LVEF ≥ 55% assessed by echocardiography.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify